Importantly, activation of TP53 by DNA damage occurs via ATM/ATR signaling and not via ARF [42,43], which implies that treatment of BMI1-expressing tumours with DNA damaging drugs should activate the TP53 pathway to induce apoptosis. This evidence concerns the gene CDKN2A and neoplasm.